Epitope Mapping Peptide Sets (EMPS) in Research

PepMix™ Peptide Pools are invaluable for studying immune responses, particularly in vaccine development and infectious disease research. JPT’s EMPS peptide pools are specifically designed to enhance the understanding of T cell reactivity and antigen-specific immune responses. Below, you will find a key study referencing JPT’s PepMix™ Peptide Pools in researches.

References with PepMix™ Peptide Pools - EMPS

2023

Immune Response Against SARS‑CoV‑2 Infection and Vaccination in a CD8α‑Defcient Patients
Arroyo‑Sánchez et al., Journal of Clinical Immunology (2023)
Product used: EMPS SARS-CoV-2 (VME1) & SARS-CoV-2 (NCAP)

2021

SARS-CoV-2-Specific T-Cell Responses After COVID-19 Recovery in Patients With Rheumatic Diseases on Immunosuppressive Therapy
Ana Lledó et al., (2021) Semin Arthritis Rheum
Products used: Epitope Mapping Peptide Set (EMPS) SARS-CoV-2 (NCAP) & SARS-CoV-2 (VME1)
Discordance Between SARS-CoV-2–specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients
Mario Fernández-Ruiz et al., (2021) Transplant Direct
Products used: Epitope Mapping Peptide Set (EMPS) SARS-CoV-2 (NCAP) & SARS-CoV-2 (VME1)

PepMix™ Peptide Pools - EMPS